{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:27:14Z","timestamp":1792672034769,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515010118"],"award-info":[{"award-number":["2021A1515010118"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69315-1","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:06:47Z","timestamp":1770739607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1617-1501","authenticated-orcid":false,"given":"Xun","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ze","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Jia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yuan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Huang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Rui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Xiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7927-9726","authenticated-orcid":false,"given":"Liang-Ru","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8259-9509","authenticated-orcid":false,"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Xiong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Ying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Jing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xiong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-5783","authenticated-orcid":false,"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-3794","authenticated-orcid":false,"given":"Yan-Qun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3125-6853","authenticated-orcid":false,"given":"Xing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"69315_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"69315_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen, Y. P. et al. Nasopharyngeal carcinoma. Lancet 394, 64\u201380 (2019).","journal-title":"Lancet"},{"key":"69315_CR3","unstructured":"Ferlay, J., Ervik, M. & Lam, F. Global Cancer Observatory: cancer today. Lyon, France: International Agency for Research on Cancer 2018. https:\/\/gco.iarc.fr\/today (IARC, 2021)."},{"key":"69315_CR4","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(21)00075-9","volume":"22","author":"X Lv","year":"2021","unstructured":"Lv, X. et al. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 716\u2013726 (2021).","journal-title":"Lancet Oncol."},{"key":"69315_CR5","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun, Y. et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 17, 1509\u20131520 (2016).","journal-title":"Lancet Oncol."},{"key":"69315_CR6","first-page":"2349","volume":"5","author":"J Welink","year":"1999","unstructured":"Welink, J., Boven, E., Vermorken, J. B., Gall, H. E. & van der Vijgh, W. J. F. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal or liver function. Clin. Cancer Res. 5, 2349\u20132358 (1999).","journal-title":"Clin. Cancer Res."},{"key":"69315_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1517\/13543784.10.1.119","volume":"10","author":"MJ McKeage","year":"2001","unstructured":"McKeage, M. J. Lobaplatin: a new antitumour platinum drug. Expert Opin. Investig. Drugs 10, 119\u2013128 (2001).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"69315_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12885-017-3080-4","volume":"17","author":"LR Ke","year":"2017","unstructured":"Ke, L. R. et al. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. BMC Cancer 17, 134 (2017).","journal-title":"BMC Cancer"},{"key":"69315_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(21)00182-0","volume":"22","author":"S Cavalieri","year":"2021","unstructured":"Cavalieri, S. & Licitra, L. Next generation platinum salt in nasopharygeal carcinoma. Lancet Oncol. 22, 577\u2013578 (2021).","journal-title":"Lancet Oncol."},{"key":"69315_CR10","doi-asserted-by":"publisher","first-page":"e31187","DOI":"10.1097\/MD.0000000000031187","volume":"101","author":"X Liang","year":"2022","unstructured":"Liang, X., Liu, Q., Yao, W. & Yang, S. Efficacy and toxicity of three concurrent chemoradiotherapy regimens in treating nasopharyngeal carcinoma: comparison among cisplatin, nedaplatin, and lobaplatin. Medicine 101, e31187 (2022).","journal-title":"Medicine"},{"key":"69315_CR11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1186\/s12885-022-09712-z","volume":"22","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis. BMC Cancer 22, 616 (2022).","journal-title":"BMC Cancer"},{"key":"69315_CR12","doi-asserted-by":"publisher","first-page":"e2138470","DOI":"10.1001\/jamanetworkopen.2021.38470","volume":"4","author":"QN Tang","year":"2021","unstructured":"Tang, Q. N. et al. Effect of concurrent chemoradiotherapy with nedaplatin vs cisplatin on the long-term outcomes of survival and toxic effects among patients with stage II to IVB nasopharyngeal carcinoma: a 5-year follow-up secondary analysis of a randomized clinical trial. JAMA Netw. Open. 4, e2138470 (2021).","journal-title":"JAMA Netw. Open."},{"key":"69315_CR13","doi-asserted-by":"publisher","first-page":"vii83","DOI":"10.1093\/annonc\/mds266","volume":"23","author":"AT Chan","year":"2012","unstructured":"Chan, A. T. et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, vii83\u2013vii85 (2012).","journal-title":"Ann. Oncol."},{"key":"69315_CR14","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N. Engl. J. Med. 381, 1124\u20131135 (2019).","journal-title":"N. Engl. J. Med."},{"key":"69315_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijc.32099","volume":"145","author":"WF Li","year":"2019","unstructured":"Li, W. F. et al. Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J. Cancer 145, 295\u2013305 (2019).","journal-title":"Int J. Cancer"},{"key":"69315_CR16","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, version 2. (NCCN, 2025)."},{"key":"69315_CR17","doi-asserted-by":"crossref","unstructured":"Lin, D. et al. Comparative analysis of hearing loss induced by cisplatin versus carboplatin in locally advanced nasopharyngeal carcinoma: early to mid-term findings. Clin. Otolaryngol. 50, 690\u2013697 (2025).","DOI":"10.1111\/coa.14299"},{"key":"69315_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.heares.2014.03.003","volume":"312","author":"MA Mujica-Mota","year":"2014","unstructured":"Mujica-Mota, M. A., Lehnert, S., Devic, S., Gasbarrino, K. & Daniel, S. J. Mechanisms of radiation-induced sensorineural hearing loss and radioprotection. Hear Res. 312, 60\u201368 (2014).","journal-title":"Hear Res."},{"key":"69315_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.prro.2023.12.009","volume":"14","author":"EM Ishak","year":"2024","unstructured":"Ishak, E. M., Gallitto, M., Golub, J. S., Sisti, M. B. & Wang, T. J. C. Radiation-induced sensorineural hearing loss and potential management. Pr. Radiat. Oncol. 14, 212\u2013215 (2024).","journal-title":"Pr. Radiat. Oncol."},{"key":"69315_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ijrobp.2004.11.002","volume":"62","author":"SA Yeh","year":"2005","unstructured":"Yeh, S. A., Tang, Y., Lui, C. C., Huang, Y. J. & Huang, E. Y. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J. Radiat. Oncol. Biol. Phys. 62, 672\u2013679 (2005).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"69315_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1055\/s-0039-1684048","volume":"40","author":"LP Rybak","year":"2019","unstructured":"Rybak, L. P., Mukherjea, D. & Ramkumar, V. Mechanisms of cisplatin-induced ototoxicity and prevention. Semin Hear. 40, 197\u2013204 (2019).","journal-title":"Semin Hear."},{"key":"69315_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.heares.2006.09.015","volume":"226","author":"LP Rybak","year":"2007","unstructured":"Rybak, L. P., Whitworth, C. A., Mukherjea, D. & Ramkumar, V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 226, 157\u2013167 (2007).","journal-title":"Hear Res."},{"key":"69315_CR23","doi-asserted-by":"publisher","first-page":"102203","DOI":"10.1016\/j.canep.2022.102203","volume":"79","author":"LK Dillard","year":"2022","unstructured":"Dillard, L. K. et al. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis. Cancer Epidemiol. 79, 102203 (2022).","journal-title":"Cancer Epidemiol."},{"key":"69315_CR24","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1002\/tox.24285","volume":"39","author":"KH Li","year":"2024","unstructured":"Li, K. H., Zhao, Y. Y., Cheng, H. L., Yang, J. J. & Chien, C. Y. Ototoxicity among cisplatin, carboplatin, and oxaliplatin in zebrafish model. Environ. Toxicol. 39, 4058\u20134065 (2024).","journal-title":"Environ. Toxicol."},{"key":"69315_CR25","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1200\/JCO.22.02775","volume":"41","author":"DF Cella","year":"2023","unstructured":"Cella, D. F. et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J. Clin. Oncol. 41, 5335\u20135344 (2023).","journal-title":"J. Clin. Oncol."},{"key":"69315_CR26","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2294::AID-CNCR17>3.0.CO;2-S","volume":"77","author":"MA List","year":"1996","unstructured":"List, M. A. et al. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale. a study of utility and validity. Cancer 77, 2294\u20132301 (1996).","journal-title":"Cancer"},{"key":"69315_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0895-4356(98)00138-3","volume":"52","author":"WN Kernan","year":"1999","unstructured":"Kernan, W. N., Viscoli, C. M., Makuch, R. W., Brass, L. M. & Horwitz, R. I. Stratified randomization for clinical trials. J. Clin. Epidemiol. 52, 19\u201326 (1999).","journal-title":"J. Clin. Epidemiol."},{"key":"69315_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ijerph8010015","volume":"8","author":"J Efird","year":"2011","unstructured":"Efird, J. Blocked randomization with randomly selected block sizes. Int J. Environ. Res. Public Health 8, 15\u201320 (2011).","journal-title":"Int J. Environ. Res. Public Health"},{"key":"69315_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13063-024-08005-z","volume":"25","author":"CL Bruce","year":"2024","unstructured":"Bruce, C. L. et al. Choosing and evaluating randomisation methods in clinical trials: a qualitative study. Trials 25, 199 (2024).","journal-title":"Trials"},{"key":"69315_CR30","unstructured":"Guidelines for random allocation in drug clinical trials of China. 5 https:\/\/www.bjdth.com.cn\/Sites\/Uploaded\/File\/2024\/07\/026385550472401280739347963.pdf (2022)."},{"key":"69315_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","volume":"398","author":"YP Chen","year":"2021","unstructured":"Chen, Y. P. et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 398, 303\u2013313 (2021).","journal-title":"Lancet"},{"key":"69315_CR32","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 22, 1162\u20131174 (2021).","journal-title":"Lancet Oncol."},{"key":"69315_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ijrobp.2019.06.2540","volume":"105","author":"AW Lee","year":"2019","unstructured":"Lee, A. W. et al. International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma. Int J. Radiat. Oncol. Biol. Phys. 105, 567\u2013580 (2019).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"69315_CR34","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox, J. D., Stetz, J. & Pajak, T. F. Toxicity Criteria Of The Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J. Radiat. Oncol. Biol. Phys. 31, 1341\u20131346 (1995).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"69315_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(18)30104-9","volume":"19","author":"LQ Tang","year":"2018","unstructured":"Tang, L. Q. et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 19, 461\u2013473 (2018).","journal-title":"Lancet Oncol."},{"key":"69315_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1177\/1740774511410994","volume":"8","author":"TR Fleming","year":"2011","unstructured":"Fleming, T. R., Odem-Davis, K., Rothmann, M. D. & Li Shen, Y. Some essential considerations in the design and conduct of non-inferiority trials. Clin. Trials 8, 432\u2013439 (2011).","journal-title":"Clin. Trials"},{"key":"69315_CR37","doi-asserted-by":"crossref","unstructured":"Odem-Davis, K. & Fleming, T. R. Adjusting for unknown bias in non-inferiority clinical trials. Stat Biopharm Res. 5, 795910 (2013).","DOI":"10.1080\/19466315.2013.795910"},{"key":"69315_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/030006059802600201","volume":"26","author":"R Kay","year":"1998","unstructured":"Kay, R. Statistical principles for clinical trials. J. Int Med Res. 26, 57\u201365 (1998).","journal-title":"J. Int Med Res."},{"key":"69315_CR39","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2012.87802","volume":"308","author":"G Piaggio","year":"2012","unstructured":"Piaggio, G. et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 308, 2594\u20132604 (2012).","journal-title":"JAMA"},{"key":"69315_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/sim.1425","volume":"22","author":"RB D\u2019Agostino","year":"2003","unstructured":"D\u2019Agostino, R. B. Non-inferiority clinical trials: concepts and issues. Stat. Med. 22, 169\u2013186 (2003).","journal-title":"Stat. Med."},{"key":"69315_CR41","unstructured":"EMA. Guideline on the choice of the non-inferiority margin (EMA, 2005)."},{"key":"69315_CR42","unstructured":"FDA. Guidance for industry: non-inferiority clinical trials (FDA, 2016)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69315-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69315-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69315-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:01:29Z","timestamp":1773972089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69315-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69315"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69315-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2604"}}